Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for PBSC Mobilization in Multiple Myeloma
NCT02572596Unknown
- Start
- Jan 2013
- Primary completion
- Dec 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Trial of recombinant human thrombopoietin in multiple myeloma (MM) (2 arms). Primary endpoint: Number of CD34+ stem/progenitor cells that are mobilized at 2 weeks. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02572596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572596.